BRAF and cancer: These effects are likely to be the consequence of the overlap between pathogenetic cancer target pathways and homeostatic pathways required for normal cardiac and vascular physiology.7, 8, 9, 10 We review the current evidence and understanding of the incidence and mechanisms of BRAF inhibitor/MEK inhibitor–associated cardiovascular toxicity.